Medical tests
On the basis of the above, a number of tests may be ordered:
An electrocardiogram (ECG)
Chest radiograph or chest x rays are frequently performed
Echocardiography can be useful in patients with known cardiac disease or aortic dissection
CT scanning is used in the diagnosis of aortic dissection
V/Q scintigraphy or CT pulmonary angiogram (when a pulmonary embolism is suspected)
Blood tests:
Troponin I or T (to indicate myocardial damage)
Complete blood count
Electrolytes and renal function (creatinine)
Liver enzymes
Creatine kinase (and CK-MB fraction in many hospitals)
D-dimer (when suspicion for pulmonary embolism is present but low)
serum lipase to exclude acute pancreatitis

Management
Management of chest pain varies with the underlying cause of the pain and the stage of care. Prehospital care
Chest pain is a common symptom encountered by emergency medical services. Aspirin increases survival in people with acute coronary syndrome and it is reasonable for EMS dispatchers to recommend it in people with no recent serious bleeding. Supplemental oxygen was used in the past for most people with chest pain but is not needed unless the oxygen saturations are less than 94% or there are signs of respiratory distress. Entonox is frequently used by EMS personnel in the prehospital environment. However, there is little evidence about its effectiveness. Hospital care
Hospital care of chest pain begins with initial survey of a persons vital signs, airway and breathing, and level of consciousness. This may also include attachment of ECG leads, cardiac monitors, intravenous lines and other medical devices depending on initial evaluation.
In 2003 Teva partnered with Eisai, giving Eisai the right to jointly market the drug for Parkinsons in the US, and to co-develop and co-market the drug for Alzheimers and other neurological diseases.It was approved by the European Medicines Agency for Parkinsons in 2005 and in the US in 2006.: 255

Research
Rasagiline was tested for efficacy in people with multiple system atrophy in a large randomized, placebo-controlled, double-blind disease-modification trial; the drug failed.Teva conducted clinical trials attempting to prove that rasagiline did not just treat symptoms, but was a disease-modifying drug - that it actually prevented the death of the dopaminergic neurons that characterize Parkinsons disease and slowed disease progression. They conducted two clinical trials, called TEMPO and ADAGIO, to try to prove this. The FDA advisory committee rejected their claim in 2011, saying that the clinical trial results did not prove that rasagiline was neuroprotective. The main reason was that in one of the trials, the lower dose was effective at slowing progression, but the higher dose was not, and this made no sense in light of standard dose-response pharmacology. See also
Selegiline
Ladostigil

References
External links
"Rasagiline". Drug Information Portal. U.S. National Library of Medicine. "Rasagiline mesylate". Drug Information Portal. U.S. National Library of Medicine.